A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3720 Tablets
This study is conducted to investigate the pharmacokinetic and safety profiles of TQB3720 in patients with metastatic castration-resistant prostate cancer.
Metastatic Castration-resistant Prostate Cancer
DRUG: TQB3720
Maximum tolerated dose (MTD), MTD was defined as the dose in which more than 2 of up to 6 patients developed a DLT., Baseline up to 28 days
Cmax, Cmax is the maximum plasma concentration of TQB3720 or metabolite(s)., 0hour, 2hour, 4hour, 8hour, 12hour, 24hour, 36hour, 48hour, 72hour, 96hour,120hour post-dose on single dose; Hour 0 of day 8、day 15、day 22；0 hour, 2 hour, 4 hour, 8 hour, 12 hour, 24 hour post-dose on multiple dose of day 28; Hour 0 of day 42 and day 56.|Tmax, To characterize the pharmacokinetics of TQB3720 by assessment of time to reach maximum plasma concentration., 0hour, 2hour, 4hour, 8hour, 12hour, 24hour, 36hour, 48hour, 72hour, 96hour,120hour post-dose on single dose; Hour 0 of day 8、day 15、day 22；0 hour, 2 hour, 4 hour, 8 hour, 12 hour, 24 hour post-dose on multiple dose of day 28; Hour 0 of day 42 and day 56.|AUC0-t, To characterize the pharmacokinetics of TQB3720 by assessment of area under the plasma concentration time curve from zero to infinity., 0hour, 2hour, 4hour, 8hour, 12hour, 24hour, 36hour, 48hour, 72hour, 96hour,120hour post-dose on single dose; Hour 0 of day 8、day 15、day 22；0 hour, 2 hour, 4 hour, 8 hour, 12 hour, 24 hour post-dose on multiple dose of day 28; Hour 0 of day 42 and day 56.
This study is conducted to investigate the pharmacokinetic and safety profiles of TQB3720 in patients with metastatic castration-resistant prostate cancer.